| Engrail Therapeutics–Ysios Capital: investment, 202403 financing round Series B totalling $157m incl co-investor Ysios Capital |
2024-03-19 |
| Zetta Genomics–Nina Capital: investment, 202402 2nd seed financing round expansion totalling £1.8m incl existing investor Nina Capital |
2024-02-08 |
| Kynexis–Ysios Capital: investment, 202311 financing round Series A totalling €57m incl co-founding + co-investor Ysios Capital |
2023-11-07 |
| SpliceBio–Optimum Strategic Communications: public relations, 202310 service existent by Optimum |
2023-10-17 |
| Tagworks Pharmaceuticals–Ysios Capital: investment, 202306 financing round Series A totalling $65m incl co-lead investor Ysios Capital |
2023-06-22 |
| Nuage Therapeutics–Asabys Partners: investment, 202306 seed financing round totalling €12m incl co-lead investor Asabys Partners |
2023-06-20 |
| Nuage Therapeutics–Sabadell: investment, 202306 seed financing round totalling €12m incl co-investor BStartup |
2023-06-20 |
| Nuage Therapeutics–SEVERAL: investment, 202306 seed financing round €12m led by Sofinnova Partners + Asabys with Innvierte + BStartup |
2023-06-20 |
| Nuage Therapeutics–Sofinnova: investment, 202306 seed financing round totalling €12m incl co-lead investor Sofinnova Partners |
2023-06-20 |
| Nuage Therapeutics–Spain (govt): investment, 202306 seed financing round totalling €12m incl co-investor Innvierte |
2023-06-20 |
| VarmX–Ysios Capital: investment, 202305 financing round Series B2 totalling €30m incl existing + co-investor Ysios Capital |
2023-05-25 |
| Oniria Therapeutics–Botín Foundation: investment, 202305 seed financing round totalling €1.28m incl lead investor Botín Foundation Mind the Gap |
2023-05-11 |
| Oniria Therapeutics–Catalonia (govt): investment, 202305 seed financing round totalling €1.28m incl public funding |
2023-05-11 |
| Oniria Therapeutics–Gemma Escarré Communications: public relations, 202305 service existent by GEC |
2023-05-11 |
| Oniria Therapeutics–OTHER: investment, 202305 seed financing round totalling €1.28m incl business angels as co-investors |
2023-05-11 |
| Oniria Therapeutics–Sabadell: investment, 202305 seed financing round totalling €1.28m incl co-investor BStartup of Banco Sabadell |
2023-05-11 |
| Oniria Therapeutics–SEVERAL: investment, 202305 seed financing round €1.28m led by Botin Foundation Mind the Gap with BStartup of Banco Sabadell |
2023-05-11 |
| Zetta Genomics–Nina Capital: investment, 202304 2nd seed financing round totalling £1.9m incl existing + lead investor Nina Capital |
2023-04-18 |
| Adcendo–Ysios Capital: investment, 202304 financing round Series A extension totalling €31m incl existing + co-lead investor Ysios Capital |
2023-04-04 |
| Sarcura–Nina Capital: investment, 202211 seed plus financing round totalling €7m incl existing + co-investor Nina Capital |
2022-11-17 |
| Immucor–Werfen: investment, 202211– acquisition $2b of Immucor from TPG ANNOUNCED |
2022-11-03 |
| Elypta–Nina Capital: investment, 202206 financing round Series A totalling $21m incl existing + co-investor Nina Capital |
2022-06-20 |
| Minoryx–Columbus Venture Partners: investment, 202205 financing round Series C incl co-lead investor Columbus Venture Partners |
2022-05-31 |
| Minoryx–Fund+: investment, 202205 financing round Series C incl existing + co-investor Fund+ |
2022-05-31 |
| Minoryx–la Caixa: investment, 202205 financing round Series C incl existing + co-lead investor Caixa Capital Risc |
2022-05-31 |
| Minoryx–SEVERAL: credit, 202205 complementary bank debt to Series C financing round (both tog totalling €51m) |
2022-05-31 |
| Minoryx–SEVERAL: investment, 202205 financing round Series C (incl complementary bank totalling €51m) led by Columbus VP + Caixa Capital Risc |
2022-05-31 |
| Minoryx–Spain (govt): investment, 202205 financing round Series C incl new + co-investor CDTI Innvierte |
2022-05-31 |
| Minoryx–Ysios Capital: investment, 202205 financing round Series C incl existing + co-investor Ysios Capital |
2022-05-31 |
| Almirall–Evotec: drug discovery services, 202205– collab multi-target RnD alliance in medical dermatology |
2022-05-19 |
| Integra Therapeutics–Columbus Venture Partners: investment, 202203 €1.5m addition to seed round from CLS Fund III bringing total seed round to €6m |
2022-03-29 |
| SpliceBio–SEVERAL: investment, 202202 financing round Series A €50m co-led by UCB Ventures + Ysios Capital |
2022-02-16 |
| Zetta Genomics–Nina Capital: investment, 202202 seed financing round totalling £2.5m incl lead investor Nina Capital |
2022-02-01 |
| NorthSea Therapeutics–Ysios Capital: investment, 202112 financing round Series C totalling $80m incl new + co-lead investor Ysios Capital |
2021-12-17 |
| Corteria Pharmaceuticals–Invivo Capital: investment, 202112 seed financing round totalling €12m incl co-investor Invivo Capital |
2021-12-09 |
| Integra Therapeutics–Advent France Biotechnology: investment, 202112 seed financing round totalling €4.5m incl investor Advent France Biotechnology |
2021-12-02 |
| Integra Therapeutics–Gemma Escarré Communications: public relations, 202112 service existent by GEC |
2021-12-02 |
| Integra Therapeutics–Invivo Capital: investment, 202112 seed financing round totalling €4.5m incl investor Invivo Capital |
2021-12-02 |
| Integra Therapeutics–SEVERAL: investment, 202112 seed financing round €4.5m with Advent FB + Invivo Capital + Takeda Ventures |
2021-12-02 |
| Integra Therapeutics–Takeda: investment, 202112 seed financing round totalling €4.5m incl investor Takeda Ventures |
2021-12-02 |
| Biotest–Grifols: investment, 202109–202204 public cash tender offer €895m for remaining 54.5% of shares at €34/ordinary share + €37/preferred share |
2021-09-17 |
| Creat (CN)–Grifols: investment, 202109 acquisition 100% of Tiancheng Germany owning 90% voting rights + 45% total capital of Biotest for €773m cash |
2021-09-17 |
| Cytoki Pharma–Ysios Capital: investment, 202105 financing round Series A totalling $45m incl co-investor Ysios Capital |
2021-05-05 |
| Adcendo–Ysios Capital: investment, 202104 financing round Series A totalling €51m incl co-lead investor Ysios Capital |
2021-04-29 |
| Synendos Therapeutics–Ysios Capital: investment, 202104 investment by new investor Ysios Capital extends financing round Series A to CHF24m |
2021-04-20 |
| Inbrain Neuroelectronics–SEVERAL: investment, 202103 financing round Series A €14.35m led by Asabys Partners incl follow-on from ICF VTII |
2021-03-26 |
| Almirall–MC2 Therapeutics: Wynzora Cream, 202102– license excl to commercialise Wynzora Cream for plaque psoriasis in Europe for Almirall |
2021-02-17 |
| MedLumics–la Caixa: investment, 202102 financing round totalling €18m incl existing investor Caixa Capital Risc |
2021-02-10 |
| Minoryx–Image Box: public relations, 202101 service existent by Image Box Communications |
2021-01-26 |
| CorWave–Ysios Capital: investment, 202101 financing round Series C totalling €35m incl existing + co-investor Ysios Capital |
2021-01-06 |
| Sarcura–Nina Capital: investment, 202011 seed financing round totalling €2.5m incl investor Nina Capital |
2020-11-19 |
| SparingVision–Ysios Capital: investment, 202010 financing round totalling €44.5m incl new + co-investor Ysios Capital |
2020-10-21 |
| Prolytic–Kymos: investment, 202009 strategic merger of Polytic GmbH + Kymos SL |
2020-09-28 |
| Galecto–Ysios Capital: investment, 202009 financing round totalling $64m incl existing + co-investor Ysios Capital |
2020-09-25 |
| Lava Therapeutics–Ysios Capital: investment, 202009 financing round Series C totalling $83m incl new + co-investor Ysios Capital |
2020-09-17 |
| Ona Therapeutics–Alta Life Sciences: investment, 202006 financing round Series A totalling €30m incl new investor Alta Life Sciences |
2020-06-16 |
| Ona Therapeutics–Asabys Partners: investment, 202006 financing round Series A totalling €30m incl existing investor Sabadell Asabys |
2020-06-16 |
| Ona Therapeutics–France (govt): investment, 202006 financing round Series A totalling €30m incl new investor Bpifrance InnoBio 2 |
2020-06-16 |
| Ona Therapeutics–Fund+: investment, 202006 financing round Series A totalling €30m incl new investor Fund+ |
2020-06-16 |
| Ona Therapeutics–Optimum Strategic Communications: public relations, 202006 service existent by Optimum |
2020-06-16 |
| Ona Therapeutics–SEVERAL: investment, 202006 financing round Series A €30m |
2020-06-16 |
| Ona Therapeutics–Ysios Capital: investment, 202006 financing round Series A totalling €30m incl new investor Ysios Capital |
2020-06-16 |
| Inbrain Neuroelectronics–SEVERAL: investment, 202006 seed financing round led by Sabadell-Asabys + Alta Life Sciences |
2020-06-01 |
| Accure Therapeutics–SEVERAL: investment, 202005 financing round Series A €7.6m led by Alta Life Sciences with support from CDTI |
2020-05-26 |
| Almirall–23andMe: therapeutic antibodies, 202001– license ww to bispecific MAb blocking all 3 isoforms of IL-36 |
2020-01-09 |
| Almirall–WuXi PharmaTech: therapeutic antibodies, 202001– collab strategic RnD bispecific Abs for dermatology using WuXiBody antibody technology |
2020-01-09 |
| Riemser–Esteve: investment, 202001– acquisition €na of Riemser from Ardian by Esteve |
2020-01-08 |
| Elypta–Nina Capital: investment, 201912 late seed financing round totalling €6.1m incl co-investor Nina Capital |
2019-12-01 |
| Grifols–Shanghai RAAS: plasma products + diagnostics, 201911c– strategic alliance in China incl share swap |
2019-11-13 |
| Shanghai RAAS–Grifols: investment, 201911c acquisition 26.2% share in Shanghai RAAS via share swap as part of strategic alliance |
2019-11-13 |
| i-Dositecno–SP Industries: investment, 201910 acquisition of assets of i-Dositecno by SP Industries |
2019-10-28 |
| SP Industries–i-Dositecno: filling solutions, 201908– collab product integration to offer complete aseptic vial/syringe fill-finish lines |
2019-08-13 |
| Sanifit–Alta Life Sciences: investment, 201906 financing round Series D totalling €55.2m incl new + co-investor Alta Life Sciences |
2019-06-26 |
| Sanifit–HealthEquity: investment, 201906 financing round Series D totalling €55.2m incl existing + co-investor HealthEquity |
2019-06-26 |
| Sanifit–la Caixa: investment, 201906 financing round Series D totalling €55.2m incl existing + lead investor Caixa Capital Risc |
2019-06-26 |
| Sanifit–Ysios Capital: investment, 201906 financing round Series D totalling €55.2m incl existing + co-investor Ysios Capital |
2019-06-26 |
| Ona Therapeutics–Asabys Partners: investment, 201905 seed financing €1.5m from Sabadell Asabys Fund |
2019-05-21 |
| Adrenomed–Informa: investor conference, 201905 supply service Adrenomed presents at BioEquity Europe 2019 in Barcelona |
2019-05-20 |
| Devicare–SEVERAL: investment, 201905– crowdfunding compaign via Capital Cell platform |
2019-05-06 |
| Diem Labs–Devicare: medical device, 201905– collab marketing of Lit-Control in the US by Diem Labs LLC |
2019-05-03 |
| SOM Biotech–SEVERAL: investment, 201903 financing round €7m led by European family holding |
2019-03-07 |
| Grifols–Rigel: fostamatinib, 201901– collab + license $30m upront + $297.5m milestones + royalties all indications in Europe + Turkey |
2019-01-23 |
| Senolytic Therapeutics–Life Biosciences: investment, 201901 acquisition of Senolytic by Life Biosciences |
2019-01-09 |
| Galecto–Ysios Capital: investment, 201810 financing round Series C totalling $79m incl new + co-lead investor Ysios Capital |
2018-10-26 |
| Minoryx–SEVERAL: investment, 201809 financing round Series B €21.3m led by Fund+ with SFPI + SRIW + Sambrinvest + all Series A investors |
2018-09-26 |
| Almirall–Evotec: drug discovery services, 201809– collab RnD therapies for dermatological diseases |
2018-09-17 |
| Grifols–EU (govt): credit, 201809–2028 loan €85m from European Investment Bank |
2018-09-07 |
| Molecular Discovery–Lead Molecular Design: mass spectrometry s/w, 201808 distribution existent of MetaSite + MassMetaSite et al by Molecular Discovery |
2018-08-04 |
| Pharma Omnium–NuPharm: investment, 201807 acquisition €na of Laboratoire Biodim from Pharma Omnium |
2018-07-03 |
| Bionure–Alta Life Sciences: investment, 201805 financing round Series A totalling €4m incl lead investor Alta Life Sciences |
2018-05-16 |
| Bionure–SEVERAL: investment, 201805 financing round Series A €4m led by Alta Life Sciences |
2018-05-16 |
| Reig Jofré–LeanBio: biosimilars, 201803– collab founding of joint venture Syna Therapeutics to develop biosimilars |
2018-03-23 |
| Aton–Grifols: investment, 201803– acquisition 100% of Haema for €220 on a debt free basis by Grifols from Aton GmbH |
2018-03-20 |
| ABAC Therapeutics–SEVERAL: investment, 201802 financing round Series A €16m led by Pontifax + incl GHSF + Caixa Capital Risc + Debiopharm + Ferrer |
2018-02-15 |
| STAT-Diagnostica–Qiagen: investment, 201801 acquisition $147m upfront cash + $44m milestones of STAT-Dx by Qiagen |
2018-01-31 |
| Intelligent Pharma–Mind the Byte: investment, 201801 acquisition €na 100% of Intelligent Pharma by Mind the Byte |
2018-01-11 |
| Mind the Byte–SEVERAL: investment, 201801– financing round €3m (1/3 of company) to finance acquisition of Intelligent Pharma PLANNED |
2018-01-11 |
| Ahead Therapeutics–SEVERAL: investment, 2018 funding total private investment attracted Jan to May 2018 |
2018-01-01 |
| Elma Care–SEVERAL: investment, 2018 funding total private investment attracted Jan to May 2018 |
2018-01-01 |
| Mediquo–SEVERAL: investment, 2018 funding total private investment attracted Jan to May 2018 |
2018-01-01 |
![[LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal](/images/basics/lse-life-sciences-europe-portal-logo.svg){kind=logo}
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
